Angiotensin II Type-I receptor blocker, candesartan, improves brachial-ankle pulse wave velocity independent of its blood pressure lowering effects in type 2 diabetes patients

Internal Medicine

Volumn 47, Issue 23, 2008, Pages 2013-2018

  Ishii, Hideto ^a,b   Tsukada, Toyohiro ^b   Yoshida, Masayuki ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Tama Nanbu Regional Hospital   (Japan)

Author keywords

AT1 receptor blocker; Pulse wave velocity; Type 2 diabetes mellitus

Indexed keywords

ADALAT CR; AMLODIPINE; AMLODIPINE BESYLATE; C REACTIVE PROTEIN; CANDESARTAN; CANDESARTAN HEXETIL; HEMOGLOBIN A1C; INTERLEUKIN 6; NIFEDIPINE; UNCLASSIFIED DRUG;

AGED; ANKLE BRACHIAL INDEX; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANKLE BRACHIAL INDEX; BENZIMIDAZOLES; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; MIDDLE AGED; TETRAZOLES;

EID: 61749099337     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.1162     Document Type: Article

References (30)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853, 1998(Erratum in: Lancet 354:602, 1999).
2. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/ angiotensin II crosstalk. J Clin Invest 100: 2158-2169, 1997.
3. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105: 1605-1612, 2000.
4. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 103: 448-454, 2001.
5. Andersson RG, Jacobsson L, Persson K. Angiotensin converting enzyme inhibitors and atherosclerosis. J Physiol Pharmacol 45: 13-25, 1994.
6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979, 1997.
7. Ikeda U, Ito T, Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol 24: 701-704, 2001.
8. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126, 1999.
9. Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med 45: 361-378, 1994.
10. Wu L, Iwai M, Nakagami H, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 104: 2716-2721, 2001.
11. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 198: 22-28, 2008.
12. Ogihara T, Nakao K, Fukui T, et al. for the Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 51: 393-398, 2008.
13. Imanishi R, Seto S, Toda G, et al. High brachial-ankle pulse wave velocity is an independent predictor of the presence of coronary artery disease in men. Hypertens Res 27: 71-78, 2004.
14. Ogawa O, Onuma T, Kubo S, Mitsuhashi N, Muramatsu C, Kawamori R. Brachial-ankle pulse wave velocity and symptomatic cerebral infarction in patients with type 2 diabetes: a cross-sectional study. Cardiovasc Diabetol 2: 10, 2003.
15. Matsuoka O, Otsuka K, Murakami S, et al. Arterial stiffness independently predicts cardiovascular events in an elderly community - Longitudinal Investigation for the Longevity and Aging in Hokkaido County (LILAC) study. Biomed Pharmacother suppl 1: S40-S44, 2005.
16. Kobayashi K, Akishita M, Yu W, Hashimoto M, Ohni M, Toba K. Interrelationship between non-invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intimamedia thickness and pulse wave velocity. Atherosclerosis 173: 13-18, 2004.
17. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci U S A 84: 9238-9242, 1987.
18. Taniwaki H, Kawagishi T, Emoto M, et al. Correlation between the intima-media thickness of the carotid artery and aortic pulsewave velocity in patients with type 2 diabetes. Vessel wall properties in type 2 diabetes. Diabetes Care 22: 1851-1857, 1999.
19. Ibata J, Sasaki H, Kakimoto T, et al. Cardio-ankle vascular index measures arterial wall stiffness independent of blood pressure. Diabetes Res Clin Pract 80: 265-270, 2008.
20. Takai S, Jin D, Sakaguchi M, et al. Comparative effects of candesartan and amlodipine in a monkey atherosclerotic model. Hypertens Res 27: 517-522, 2004.
21. Doran DE, Weiss D, Zhang Y, Griendling KK, Taylor WR. Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species. Atherosclerosis 195: 39-47, 2007.
22. Kobayashi N, Mori Y, Nakano S, et al. TCV-116 stimulates eNOS and caveolin-1 expression and improves coronary microvascular remodeling in normotensive and angiotensin II-induced hypertensive rats. Atherosclerosis 158: 359-368, 2001.
23. Pietri P, Vyssoulis G, Vlachopoulos C, et al. Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens 24: 2231-2238, 2006.
24. Kim JS, Kang TS, Kim JB, et al. Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis 192: 401-406, 2007.
25. Kullo IJ, Seward JB, Bailey KR, et al. C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community. Am J Hypertens 18: 1123-1129, 2005.
26. Yasmin MC, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-Reactive Protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 24: 969-974, 2004.
27. Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 194: 123-130, 2007.
28. Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40: 872-879, 2002.
29. Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43: 1003-1010, 2004.
30. Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022-2031, 2004.